Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants

• Published in: Vaccines (Basel) Vol. 12; no. 5; p. 518
• Main Authors: Wagner, Angelika, Garner-Spitzer, Erika, Auer, Claudia, Gattinger, Pia, Zwazl, Ines, Platzer, René, Orola-Taus, Maria, Pichler, Peter, Amman, Fabian, Bergthaler, Andreas, Huppa, Johannes B., Stockinger, Hannes, Zielinski, Christoph C., Valenta, Rudolf, Kundi, Michael, Wiedermann, Ursula
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.05.2024
• Subjects: Antibodies; Antigens; Austria; B cells; Blood; breakthrough infection; Carfilzomib; CD38 antigen; COVID-19; COVID-19 vaccines; Cross-protection; Cytokines; Development and progression; Drug dosages; Ethylenediaminetetraacetic acid; Health aspects; immune cell depletion; immune response; Immunological memory; Immunology; immunosuppression; Immunotherapy; Infection; Infections; Inflammatory bowel disease; Lymphocytes; Memory (Computers); Memory cells; Monoclonal antibodies; Monoclonal gammopathy; Morbidity; Mortality; mRNA; Multiple myeloma; Peptides; Proteins; RNA; SARS-CoV-2 vaccination; Severe acute respiratory syndrome coronavirus 2; Software; Stem cell transplantation; Stem cells; Transplantation; Vaccination; Vaccines; Viral diseases; Austria; United States > US; Germany; SARS-CoV-2 vaccination; multiple myeloma; B memory cells; immune response; breakthrough infection; immune cell depletion; immunosuppression

Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with increased risk for COVID-19 morbidity and mortality but impaired responses to primary mRNA SARS-CoV-2 vaccination. The effects of booster vaccinations and breakthrough infections (BTIs) on antibody (Ab) levels and c...